Stock Events

Stock Events

Protalix BioTherapeutics 

$2.30
46
-$0.02-0.86% 20:00 Today
+$0.00+0%20:00After hours

Statistics

Day High
2.35
Day Low
2.3
52W High
3.19
52W Low
1.36
Volume
10,861,104
Avg. Volume
-
Mkt Cap
185.31M
P/E Ratio
12.11
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.05
0.04
0.13
0.22
Expected EPS
-0.01
Actual EPS
N/A

Financials

-12.52%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
52.74MRevenue
-6.6MNet Income

Analyst Ratings

12.00Average Price Target
The highest estimate is 12.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PLX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap138.61B
Pfizer competes in the biopharmaceutical space, developing drugs that could directly compete with Protalix's treatments.
AMGEN
AMGN
Mkt Cap201.93B
Amgen focuses on novel therapies in various areas, including those that Protalix targets, making them direct competitors.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences operates in the biopharmaceutical field, producing competitive drugs in the same therapeutic areas as Protalix.
Biogen
BIIB
Mkt Cap31.91B
Biogen develops therapies for diseases with unmet medical needs, potentially competing with Protalix's product pipeline.
Vertex Pharmaceuticals
VRTX
Mkt Cap134.02B
Vertex Pharmaceuticals is involved in creating treatments for serious diseases, some of which may overlap with Protalix's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals develops biologic medicines, including for conditions that Protalix is also targeting.
Novo Nordisk
NVO
Mkt Cap223.19B
Novo Nordisk is a global healthcare company with products that could compete in the therapeutic areas Protalix is involved in.
Sanofi
SNY
Mkt Cap103.32B
Sanofi develops a wide range of medicines, including those in areas where Protalix is seeking to make an impact.

About

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Show more...
CEO
Mr. Dror Bashan
Employees
231
Country
United States
ISIN
US74365A3095

Listings

STU
DE
PBDA.STU
MU
DE
PBDA.MU
XASE
US
PLX
F
DE
PBDA.F

0 Comments

Share your thoughts

FAQ

What is Protalix BioTherapeutics stock price today?▼
The current price of PLX is $2.30 USD — it has decreased by -0.86% in the past 24 hours. Watch Protalix BioTherapeutics stock price performance more closely on the chart.
What is Protalix BioTherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Protalix BioTherapeutics stocks are traded under the ticker PLX.
Is Protalix BioTherapeutics stock price growing?▼
PLX stock has fallen by -2.13% compared to the previous week, the month change is a +16.16% rise, over the last year Protalix BioTherapeutics has showed a +49.35% increase.
What is Protalix BioTherapeutics market cap?▼
Today Protalix BioTherapeutics has the market capitalization of 185.31M
When is the next Protalix BioTherapeutics earnings date?▼
Protalix BioTherapeutics is going to release the next earnings report on August 17, 2026.
What were Protalix BioTherapeutics earnings last quarter?▼
PLX earnings for the last quarter are 0.22 USD per share, whereas the estimation was -0.01 USD resulting in a +2,300% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Protalix BioTherapeutics revenue for the last year?▼
Protalix BioTherapeutics revenue for the last year amounts to 52.74M USD.
What is Protalix BioTherapeutics net income for the last year?▼
PLX net income for the last year is -6.6M USD.
How many employees does Protalix BioTherapeutics have?▼
As of July 06, 2026, the company has 231 employees.
In which sector is Protalix BioTherapeutics located?▼
Protalix BioTherapeutics operates in the Health & Wellness sector.
When did Protalix BioTherapeutics complete a stock split?▼
The last stock split for Protalix BioTherapeutics was on December 20, 2019 with a ratio of 1:10.
Where is Protalix BioTherapeutics headquartered?▼
Protalix BioTherapeutics is headquartered in Hackensack, United States.